Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a ...

For the quarter ended March 31, 2025, Orchid received $133.0 million in scheduled and unscheduled principal repayments and prepayments, which equated to a 3-month constant prepayment rate ("CPR”) of ...